AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02880696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Random stimulation sequence
Description: Vibrotactile stimulation of the right hand with random intervals and random omissions
Study NCT02880696 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DCS
Description: Near-infrared imaging of the neurovascular response in the left somatosensory cortex
Study NCT02880696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCS
Description: Near-infrared imaging of the neurovascular response in the left somatosensory cortex
Study NCT02375789 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active RhinoChill
Description: The device is intended for use for the reduction of temperature via the nasal cavity.~The RhinoChill® System is a British Standards Institution Kite-Marked device that is currently commercially available in Europe. The RhinoChill® device is intended for temperature reduction in patients via the nasal cavity.
Study NCT02375789 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo RhinoChill
Description: The placebo RhinoChill device looks and functions in an identical way to the active RhinoChill. All components are used, however through some minor changes in the design of the device it now provides a sufficient placebo treatment to the patient.
Study NCT04124679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acupoint Stimulation
Description: patients received Transcutaneous Electrical Acupoint Stimulation for 30 mins on the acupoints
Study NCT00548652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE
Description: is a VA based multidesciplinary weight loss intervention
Study NCT00548652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: medical crisis councelling
Description: group counselling sessions
Study NCT00548652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyphenidate
Description: methyphenidate will be used to treat apathy dose 10mg bid
Study NCT04197310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg, intravenously, Day 1 and 15 of a 28 day cycle
Study NCT04197310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 40mg, orally, Daily for a 28 day cycle
Study NCT03931135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Cyclizine versus IV Dexamethasone for prevention of nausea and vomiting after intrathecal morphine in patients undergoing cesarean section
Description: The first group (Dexamethasone) will receive 8 mg IV dexamethasone within 1-2 minutes after the umbilical cord is clamped.~The second group (Cyclizine) will receive 50 mg cyclizine within 1-2 minutes after the umbilical cord is clamped
Study NCT03428919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
Study NCT03428919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: In IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.
Study NCT00588068 — intervention group
Intervention type: OTHER
Intervention: Tumor and Marrow Markers
Description: Tumor and Marrow Markers
Study NCT00199043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Study NCT00199043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Study NCT02291653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath
Description: video-laryngoscopy
Study NCT02291653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: direct-laryngoscopy
Study NCT03633500 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Placebo Comparator: Sterile water: 0.2 ml of sterile water is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The liquid is given time to get absorbed, any pooled liquid is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
Study NCT03633500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Breastmilk
Description: Experimental: Breastmilk: 0.2 ml of mothers' own colostrum/ breast milk is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The colostrum is given time to get absorbed, any pooled milk is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours. independently sucks at breast, bottle or cup feed
Study NCT00927641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen Patch
Description: Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
Study NCT00927641 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Two placebo patches placed on target ankle once daily for 14 days
Study NCT01202591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration
Study NCT01202591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration
Study NCT04992533 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long-duration tourniquet
Description: Tourniquet is used in arthroscopic exploration and high tibial osteotomy
Study NCT02763683 — intervention group
Intervention type: RADIATION
Intervention: PiB and VAT
Description: There is no intervention for this study. The PiB and VAT are used during the PET procedures to help to identify any excessive abnormal proteins in the brain.
Study NCT04427332 — intervention group
Intervention type: OTHER
Intervention: Investigation of smell and taste disorders
Description: The study consists of an epidemiological investigation by means of a prospective observational study with the aim of investigating the demographic and clinical factors related to the sense of smell and taste in patients with Sars Cov 2 infection.
Study NCT01718418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test meal
Study NCT01718418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reference
Study NCT03027544 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Tomotherapy: The regular fraction modes were as follows: a. lesions≥3 cm:52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm:36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm: 40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem:50-60Gy/2.5-3Gy/20f; 3. multiple lesions with large lesion: whole brain radiation (WBRT) with 40Gy/2Gy/20f and concurrent boost of 60Gy/3Gy/20f of the lesions.~TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.
Study NCT01410617 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemodialysis
Description: 3 sessions hemodialysis before CABG
Study NCT02553356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT2385
Study NCT02711917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAC 0.5
Description: 0.5 MAC Sevoflurane
Study NCT04992533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short-duration tourniquet
Description: Tourniquet is only used for arthroscopic exploration
Study NCT01233206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin pre-treatment and co-administration
Study NCT01233206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: Placebo pre-treatment and co-administration
Study NCT02711917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAC 0.75
Description: 0.75 MAC Sevoflurane
Study NCT02711917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAC 1.0
Description: 1.0 MAC Sevoflurane
Study NCT02711917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol consumption
Study NCT02711917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: Etomidate consumption
Study NCT04141176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spiri+
Description: CPAP Spiri+ will be weared during one night for each included patient.The validation of the CPAP Spiri+ algorithm will be in the first 10 patients and appreciation of overall clinical efficacy on the 10 last OSAS.
Study NCT03372941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalbavancin
Description: Dalbavancin, a lipoglycopeptide antibiotic, has been approved by the FDA for the treatment of ABSSSI caused by Gram-positive bacteria. A single dose of dalbavancin will be administered in the Emergency Department followed by discharge with close outpatient infectious disease clinic follow-up.
Study NCT02711917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Consumption of Rocuronium
Study NCT05103852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: vigilant patient installed in the MRI with compatible ECG electrodes for synchronization and monitoring, blood pressure cuff for monitoring, cardiac antenna. Sterile drape over the femoral region, femoral local anesthesia, femoral venipuncture, Swan Ganz probe venous navigation (CE marking, MRI compatible at 1.5T) with balloon inflated with 2 cc of gadolinium, navigation under real time SSFP cine sequence.
Study NCT01596062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simulect®
Description: Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection. The solution should be used immediately after reconstitution. The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®). Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).
Study NCT01596062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simulect®
Description: Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection. The solution should be used immediately after reconstitution. The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®). Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).
Study NCT01596062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoral®
Description: Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs.
Study NCT01596062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoral®
Description: Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs.
Study NCT01596062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certican®
Description: Certican® was provided to the study center in its commercial package as 0.75, 0.5 and 0.25 mg tablets in thermoformed blister packs.
Study NCT01596062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic®
Description: Myfortic® was administered orally b.i.d. with a 12-hour interval. Tablets could be taken either with or outside meals but consistently throughout the study. To maintain the integrity of the enteric coating, tablets were not to be crushed. Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center. Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks. Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study. Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups. It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.
Study NCT01596062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic®
Description: Myfortic® was administered orally b.i.d. with a 12-hour interval. Tablets could be taken either with or outside meals but consistently throughout the study. To maintain the integrity of the enteric coating, tablets were not to be crushed. Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center. Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks. Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study. Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups. It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.
Study NCT01596062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroid i.v. therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center. Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day. Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.
Study NCT01596062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroid i.v. therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center. Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day. Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.
Study NCT03159260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theraworx
Description: Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
Study NCT03159260 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
Study NCT03718091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Description: M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.
Study NCT02117687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboxymethylcellulose 0.5%/glycerin 0.9%
Description: 1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
Study NCT03730402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: utilizing local anesthetic to perform a regional block under laparoscopic guidance
Study NCT03730402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel 266 milligram Per 20 ML Injection
Description: utilizing local anesthetic to perform a regional block under laparoscopic guidance
Study NCT03730402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: placebo injection of saline
Study NCT03664349 — intervention group
Intervention type: DEVICE
Intervention: SuperEar9000
Description: Handheld hearing amplifier, not FDA regulated.
Study NCT00323011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab
Study NCT00323011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab
Study NCT02358291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open discectomy
Description: The open discectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
Study NCT02358291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microendoscopic discectomy
Description: Microendoscopic discectomy combines standard lumbar microsurgical techniques with endoscope, enabling surgeons to successfully address free-fragment disc pathologic factors and lateral recess stenosis.
Study NCT02358291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transforaminal endoscopic lumbar discectomy
Description: transforaminal endoscopic lumbar discectomy removes the intervertebral disc portion through the intervertebral foramen
Study NCT01714791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients exercise at a heart rate corresponding to 65% of baseline Vo2peak. Each exercise training session takes 40-60 minutes. Exercise time is apportioned as follows: 42% on the treadmill, 33% on the circle ergometer and 25% on the arm cranking device. All patients exercise under close supervision 3 days per week for a total duration of 12 weeks.
Study NCT01714791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients exercise at a heart rate corresponding to 65% of baseline Vo2peak. Each exercise training session takes 40-60 minutes. Exercise time is apportioned as follows: 42% on the treadmill, 33% on the circle ergometer and 25% on the arm cranking device. All patients exercise under close supervision 3 days per week for a total duration of 12 weeks.
Study NCT01714791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Description: Patients receive 4 osteopathic treatments (OT). OT is performed in week 4, 5, 8 and 12 postoperative. Depending on what is found in the patient, treatments consist mostly of one or more of the following approaches:~* Structural High Velocity Low Amplitude-techniques.~* Muscle Energy Techniques.~* General osteopathic mobilisations.~* Functional techniques (Sutherland-, Jones-techniques,...) including inhibition techniques.~* Fascia techniques.~* Soft tissue- and connective tissue techniques.~* Neurovisceral and neurolymphatic reflex techniques.~* Fluidal techniques (lymphatic manipulative techniques,...).~* Visceral manipulations.~* Neurocranial and viscerocranial techniques.
Study NCT02117687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium hyaluronate 0.18%
Description: 1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
Study NCT02469571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Winclove 607
Description: multispecies probiotic
Study NCT02469571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02761967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Women from the 20th week of moderate physical exercise performed in water character designed following the guidelines in the SWEP method will end in week 37 of gestation. After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes.
Study NCT03950921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Safety Display
Description: Digital display of catheter and pressure injury information in patient hospital room
Study NCT03689309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Flow Oxygen SBT
Description: The patient is disconnected from the ventilator and remains 30 minutes without support but high flow oxygen delivered through a dedicated piece that is usually connected on tracheotomy.